AI-Powered Drug Formulation Market Size, Share, and Trends 2025 to 2034

AI-Powered Drug Formulation Market (By Component: Software Platforms, Services, Hardware & Infrastructure; By Technology: Machine Learning & Deep Learning, Natural Language Processing for literature mining, Predictive Modeling & Simulation, Generative AI & Neural Networks, Hybrid AI; By Application / Use Case: Excipient Compatibility Prediction, Formulation Design, Stability & Shelf-life Prediction, High-Throughput Screening Optimization, Personalized & Precision Medicine Formulations, Advanced Therapy Formulations; By Drug Type: Small Molecules, Biologics, Nucleic Acid-Based Drugs, Cell & Gene Therapy Payloads, Vaccines; By Dosage Form: Oral Solid Dosage, Parenterals, Inhalation & Pulmonary Drug Delivery, Transdermal / Topical Formulations, Nasal / Mucosal Delivery, Advanced Delivery Systems;) - Global Industry Analysis, Size, Trends, Leading Companies, Regional Outlook, and Forecast 2025 to 2034

Last Updated : October 2025  |  Report Code : 6957  |  Category : Healthcare  |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology 

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on AI-Powered Drug Formulation Market 

5.1. COVID-19 Landscape: AI-Powered Drug Formulation Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global AI-Powered Drug Formulation Market, By Component

8.1. AI-Powered Drug Formulation Market, by Component

8.1.1. Software Platforms

8.1.1.1. Market Revenue and Forecast

8.1.2. Services

8.1.2.1. Market Revenue and Forecast

8.1.3. Hardware & Infrastructure

8.1.3.1. Market Revenue and Forecast

Chapter 9. Global AI-Powered Drug Formulation Market, By Technology

9.1. AI-Powered Drug Formulation Market, by Technology

9.1.1. Machine Learning & Deep Learning

9.1.1.1. Market Revenue and Forecast

9.1.2. Natural Language Processing (NLP) for literature mining

9.1.2.1. Market Revenue and Forecast

9.1.3. Predictive Modeling & Simulation

9.1.3.1. Market Revenue and Forecast

9.1.4. Generative AI & Neural Networks (novel formulation design)

9.1.4.1. Market Revenue and Forecast

9.1.5. Reinforcement Learning (process optimization)

9.1.5.1. Market Revenue and Forecast

9.1.6. Hybrid AI (AI + mechanistic models)

9.1.6.1. Market Revenue and Forecast

Chapter 10. Global AI-Powered Drug Formulation Market, By Application / Use Case 

10.1. AI-Powered Drug Formulation Market, by Application / Use Case

10.1.1. Excipient Compatibility Prediction

10.1.1.1. Market Revenue and Forecast

10.1.2. Formulation Design & Optimization (IR, MR, ODT, biologics formulations)

10.1.2.1. Market Revenue and Forecast

10.1.3. Stability & Shelf-life Prediction

10.1.3.1. Market Revenue and Forecast

10.1.4. Bioavailability & Pharmacokinetic (PK) Simulation

10.1.4.1. Market Revenue and Forecast

10.1.5. High-Throughput Screening (HTS) Optimization

10.1.5.1. Market Revenue and Forecast

10.1.6. Personalized & Precision Medicine Formulations

10.1.6.1. Market Revenue and Forecast

10.1.7. Advanced Therapy Formulations (cell/gene therapy delivery)

10.1.7.1. Market Revenue and Forecast

Chapter 11. Global AI-Powered Drug Formulation Market, By Drug Type

11.1. AI-Powered Drug Formulation Market, by Drug Type

11.1.1. Small Molecules

11.1.1.1. Market Revenue and Forecast

11.1.2. Biologics (proteins, peptides, mAbs)

11.1.2.1. Market Revenue and Forecast

11.1.3. Nucleic Acid-Based Drugs (siRNA, mRNA, DNA)

11.1.3.1. Market Revenue and Forecast

11.1.4. Cell & Gene Therapy Payloads

11.1.4.1. Market Revenue and Forecast

11.1.5. Vaccines (traditional and mRNA-based)

11.1.5.1. Market Revenue and Forecast

Chapter 12. Global AI-Powered Drug Formulation Market, By Dosage Form

12.1. AI-Powered Drug Formulation Market, by Dosage Form

12.1.1. Oral Solid Dosage (tablets, capsules)

12.1.1.1. Market Revenue and Forecast

12.1.2. Parenterals (injectables, biologics formulations)

12.1.2.1. Market Revenue and Forecast

12.1.3. Inhalation & Pulmonary Drug Delivery

12.1.3.1. Market Revenue and Forecast

12.1.4. Transdermal / Topical Formulations

12.1.4.1. Market Revenue and Forecast

12.1.5. Nasal / Mucosal Delivery

12.1.5.1. Market Revenue and Forecast

12.1.6. Advanced Delivery Systems (liposomes, nanoparticles, LNPs)

12.1.6.1. Market Revenue and Forecast

Chapter 13. Global AI-Powered Drug Formulation Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Component

13.1.2. Market Revenue and Forecast, by Technology

13.1.3. Market Revenue and Forecast, by Application / Use Case

13.1.4. Market Revenue and Forecast, by Drug Type

13.1.5. Market Revenue and Forecast, by Dosage Form

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Component

13.1.6.2. Market Revenue and Forecast, by Technology

13.1.6.3. Market Revenue and Forecast, by Application / Use Case

13.1.6.4. Market Revenue and Forecast, by Drug Type

13.1.6.5. Market Revenue and Forecast, by Dosage Form  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Component

13.1.7.2. Market Revenue and Forecast, by Technology

13.1.7.3. Market Revenue and Forecast, by Application / Use Case

13.1.7.4. Market Revenue and Forecast, by Drug Type

13.1.7.5. Market Revenue and Forecast, by Dosage Form

13.2. Europe

13.2.1. Market Revenue and Forecast, by Component

13.2.2. Market Revenue and Forecast, by Technology

13.2.3. Market Revenue and Forecast, by Application / Use Case

13.2.4. Market Revenue and Forecast, by Drug Type  

13.2.5. Market Revenue and Forecast, by Dosage Form  

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Component

13.2.6.2. Market Revenue and Forecast, by Technology

13.2.6.3. Market Revenue and Forecast, by Application / Use Case

13.2.7. Market Revenue and Forecast, by Drug Type  

13.2.8. Market Revenue and Forecast, by Dosage Form  

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Component

13.2.9.2. Market Revenue and Forecast, by Technology

13.2.9.3. Market Revenue and Forecast, by Application / Use Case

13.2.10. Market Revenue and Forecast, by Drug Type

13.2.11. Market Revenue and Forecast, by Dosage Form

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Component

13.2.12.2. Market Revenue and Forecast, by Technology

13.2.12.3. Market Revenue and Forecast, by Application / Use Case

13.2.12.4. Market Revenue and Forecast, by Drug Type

13.2.13. Market Revenue and Forecast, by Dosage Form

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Component

13.2.14.2. Market Revenue and Forecast, by Technology

13.2.14.3. Market Revenue and Forecast, by Application / Use Case

13.2.14.4. Market Revenue and Forecast, by Drug Type

13.2.15. Market Revenue and Forecast, by Dosage Form

13.3. APAC

13.3.1. Market Revenue and Forecast, by Component

13.3.2. Market Revenue and Forecast, by Technology

13.3.3. Market Revenue and Forecast, by Application / Use Case

13.3.4. Market Revenue and Forecast, by Drug Type

13.3.5. Market Revenue and Forecast, by Dosage Form

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Component

13.3.6.2. Market Revenue and Forecast, by Technology

13.3.6.3. Market Revenue and Forecast, by Application / Use Case

13.3.6.4. Market Revenue and Forecast, by Drug Type

13.3.7. Market Revenue and Forecast, by Dosage Form

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Component

13.3.8.2. Market Revenue and Forecast, by Technology

13.3.8.3. Market Revenue and Forecast, by Application / Use Case

13.3.8.4. Market Revenue and Forecast, by Drug Type

13.3.9. Market Revenue and Forecast, by Dosage Form

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Component

13.3.10.2. Market Revenue and Forecast, by Technology

13.3.10.3. Market Revenue and Forecast, by Application / Use Case

13.3.10.4. Market Revenue and Forecast, by Drug Type

13.3.10.5. Market Revenue and Forecast, by Dosage Form

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Component

13.3.11.2. Market Revenue and Forecast, by Technology

13.3.11.3. Market Revenue and Forecast, by Application / Use Case

13.3.11.4. Market Revenue and Forecast, by Drug Type

13.3.11.5. Market Revenue and Forecast, by Dosage Form

13.4. MEA

13.4.1. Market Revenue and Forecast, by Component

13.4.2. Market Revenue and Forecast, by Technology

13.4.3. Market Revenue and Forecast, by Application / Use Case

13.4.4. Market Revenue and Forecast, by Drug Type

13.4.5. Market Revenue and Forecast, by Dosage Form

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Component

13.4.6.2. Market Revenue and Forecast, by Technology

13.4.6.3. Market Revenue and Forecast, by Application / Use Case

13.4.6.4. Market Revenue and Forecast, by Drug Type

13.4.7. Market Revenue and Forecast, by Dosage Form

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Component

13.4.8.2. Market Revenue and Forecast, by Technology

13.4.8.3. Market Revenue and Forecast, by Application / Use Case

13.4.8.4. Market Revenue and Forecast, by Drug Type

13.4.9. Market Revenue and Forecast, by Dosage Form

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Component

13.4.10.2. Market Revenue and Forecast, by Technology

13.4.10.3. Market Revenue and Forecast, by Application / Use Case

13.4.10.4. Market Revenue and Forecast, by Drug Type

13.4.10.5. Market Revenue and Forecast, by Dosage Form

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Component

13.4.11.2. Market Revenue and Forecast, by Technology

13.4.11.3. Market Revenue and Forecast, by Application / Use Case

13.4.11.4. Market Revenue and Forecast, by Drug Type

13.4.11.5. Market Revenue and Forecast, by Dosage Form

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Component

13.5.2. Market Revenue and Forecast, by Technology

13.5.3. Market Revenue and Forecast, by Application / Use Case

13.5.4. Market Revenue and Forecast, by Drug Type

13.5.5. Market Revenue and Forecast, by Dosage Form

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Component

13.5.6.2. Market Revenue and Forecast, by Technology

13.5.6.3. Market Revenue and Forecast, by Application / Use Case

13.5.6.4. Market Revenue and Forecast, by Drug Type

13.5.7. Market Revenue and Forecast, by Dosage Form

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Component

13.5.8.2. Market Revenue and Forecast, by Technology

13.5.8.3. Market Revenue and Forecast, by Application / Use Case

13.5.8.4. Market Revenue and Forecast, by Drug Type

13.5.8.5. Market Revenue and Forecast, by Dosage Form

Chapter 14. Company Profiles

14.1. Exscientia

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Atomwise

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Schrödinger

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. BenevolentAI

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Cyclica (part of Recursion)

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. DeepMatter

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. IBM Watson Health

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Standigm

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Valo Health

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Abbott

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The major players in the AI-powered drug formulation market include Exscientia, Atomwise, Schrödinger, BenevolentAI, Cyclica (part of Recursion), DeepMatter, IBM Watson Health, Standigm, and Valo Health.

The driving factors of the AI-powered drug formulation market are the increasing integration of advanced AI technologies in drug formulation processes, enabling faster development and reduced costs.

North America region will lead the global AI-powered drug formulation market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client